WASHINGTON – President Donald Trump aims to take credit Tuesday for the speedy development of forthcoming coronavirus vaccines, even as his administration is coming under scrutiny for failing to lock in a chance to buy millions of additional doses of one of the leading contenders.
That decision could delay the delivery of a second batch of doses until manufacturer Pfizer fulfills other international contracts.The revelation, confirmed Monday by people familiar with the matter, came on the eve of Trump's plans to host a White House summit aimed at celebrating the expected approval of the first vaccine later this week.